Evidence map›Paper›PMID 42027319›Full record

ArticleStem cells international2026

Exosomes Derived From Mesenchymal Stem Cells Regulating Myotube Cell Atrophy via NF-κB Signaling Pathway.

Yibing Ke, Yongping Wang

Abstract read
In one paragraph

Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yibing KeBeijing Friendship Hospital, Capital Medical University, Beijing, China, ccmu.edu.cn.ORCID https://orcid.org/0009-0009-9786-2566
Yongping WangDepartment of Orthopedics, First Hospital of Lanzhou University, No.1 Donggang West Road Chengguan, Lanzhou, China, lzu.edu.cn.ORCID https://orcid.org/0009-0006-1382-7607

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone marrow mesenchymal stem cells (BMSCs), with their potential for multidifferentiation and self-replication, are considered effective for repairing damaged tissues. BMSCs can repair and replace damaged tissues by differentiating into effective cells and secreting some cytokines that inhibit inflammation and promote tissue repair. Recent studies suggest that BMSCs' main role in tissue repair may involve the secretion of exosomes (BMSC-Exos). Basic research has shown that exosomes can have significant effects on orthopedic diseases such as osteoarthritis, muscle tissue injury, and fractures by stimulating regeneration and reducing inflammation. However, the effect of exosomes on tumor necrosis factor (TNF-α)-induced muscle atrophy remains unclear. Therefore, this study investigated the mechanism underlying the protective effect of BMSC-Exos on TNF-α-induced C2C12 myotube atrophy. Treatment with TNF-α (20 ng/mL) for 48 h significantly reduced myotube viability and diameter, which were subsequently reversed by treatment with BMSC-Exos. BMSC-Exos treatment suppressed the expression of E3 ubiquitin ligases, including Atrogin‑1/muscle atrophy F‑box and muscle ring‑finger protein‑1 (MuRF-1). Furthermore, it increased the protein expression levels of myoblast determination protein-1 (MyoD) in TNF-α-induced myotubes. BMSC-Exos also decreased the nuclear translocation of nuclear factor-κB (NF-κB) by inhibiting the phosphorylation of κB inhibitors. These findings indicate that BMSC-Exos may protect against TNF-α-induced myotube atrophy by inhibiting the proinflammatory NF-κB pathway.

Indexed as

bone mesenchymal stem cells (BMSCs)C2C12exosomesmyotube atrophyNF-κB signaling pathwaytumor necrosis factor‑α (TNF-α)

Identifiers

PMID42027319
PMCPMC13102087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.